Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mizolastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 19/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.73 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.73 |
| ▸ | HTR2B | P41595 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 17/20 | 0.73 |
| ▸ | HTR3A | P46098 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mizolastine SCHEMBL29369194 | 0.85 | HRH1 (1.00) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| Mizolastine SCHEMBL5061 | 0.85 | HRH1 (1.00) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| Mizolastine SCHEMBL29256081 | 0.84 | HRH1 (0.98) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| Mizolastine SCHEMBL28266367 | 0.83 | HRH1 (0.95) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| SCHEMBL10483537 | 0.81 | HRH1 (0.80) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| SCHEMBL18597171 | 0.80 | HRH1 (0.74) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| SCHEMBL4443900 | 0.80 | HRH1 (0.59) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| Mizolastine SCHEMBL6273027 | 0.79 | HRH1 (0.84) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| SCHEMBL5229655 | 0.79 | HRH1 (0.73) | HRH1KCNH2CHRM1CYP2D6HTR3A | |
| SCHEMBL10482964 | 0.78 | HRH1 (0.76) | HRH1KCNH2CHRM1ADRA2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1564212-B1 | PROCESS AND INTERMEDIATES FOR OBTAINING 1-(1H-BENZIMIDAZOL-2-YL)-4-(PYRIMIDIN-2-YLAMINO)PIPERIDINE DERIVATIVES | RAGACTIVES SL (ES) | 2007-12-12 | — | — | EP | claimed |
| US-20050228006-A1 | Process and intermediates for obtaining 1-(1H-benzimidazol-2-YL)-4-(2-aminopyrimidine)piperidine derivatives | RAGACTIVES, S.L. | 2005-10-13 | — | — | US | claimed |
| EP-1564212-A1 | METHOD AND INTERMEDIA USED TO OBTAIN DERIVATIVES OF 1-(1H- BENZIMIDAZOLE-2-YL)-4-(2-AMINOPYRIMIDINE)PIPERIDINE | Ragactives, S.L. (ES) | 2005-08-17 | — | — | EP | claimed |
| JP-2009292827-A | USE OF MIZOLASTINE FOR PREPARING THERAPEUTIC AGENT FOR INFLAMMATION | SANOFI-AVENTIS | 2009-12-17 | — | — | JP | disclosed |
| EP-1564212-B1 | PROCESS AND INTERMEDIATES FOR OBTAINING 1-(1H-BENZIMIDAZOL-2-YL)-4-(PYRIMIDIN-2-YLAMINO)PIPERIDINE DERIVATIVES | RAGACTIVES SL (ES) | 2007-12-12 | — | — | EP | disclosed |
| EP-1007047-B1 | USE OF MIZOLASTINE FOR PREPARING A MEDICINE FOR TREATING INFLAMMATION | SANOFI AVENTIS (FR) | 2005-12-14 | — | — | EP | disclosed |
| US-20050228006-A1 | Process and intermediates for obtaining 1-(1H-benzimidazol-2-YL)-4-(2-aminopyrimidine)piperidine derivatives | RAGACTIVES, S.L. | 2005-10-13 | — | — | US | disclosed |
| US-20050202089-A1 | Sustained-release pharmaceutical formulations containing mizolastine | SANOFI-SYNTHELABO (FR) | 2005-09-15 | — | — | US | disclosed |
| EP-1564212-A1 | METHOD AND INTERMEDIA USED TO OBTAIN DERIVATIVES OF 1-(1H- BENZIMIDAZOLE-2-YL)-4-(2-AMINOPYRIMIDINE)PIPERIDINE | Ragactives, S.L. (ES) | 2005-08-17 | — | — | EP | disclosed |
| EP-0906101-B1 | SLOW-RELEASE PHARMACEUTICAL FORMULATIONS CONTAINING MIZOLASTIN | SANOFI SYNTHELABO (FR) | 2002-06-19 | — | — | EP | disclosed |
| US-6165507-A | Slow-release pharmaceutical formulations containing mizolastine | SYNTHELABO (FR) | 2000-12-26 | — | — | US | disclosed |
| US-6140335-A | Use of mizolastine for treating inflammatory diseases associated with 5-lipoxygenase | SANOFI-SYNTHELABO (FR) | 2000-10-31 | — | — | US | disclosed |
| EP-1007047-A1 | USE OF MIZOLASTINE FOR PREPARING A MEDICINE FOR TREATING INFLAMMATION | SYNTHELABO (FR) | 2000-06-14 | — | — | EP | disclosed |
| WO-1998047511-A1 | USE OF MIZOLASTINE FOR PREPARING A MEDICINE FOR TREATING INFLAMMATION | SANOFI-SYNTHELABO (FR) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228006-A1 | Process and intermediates for obtaining 1-(1H-benzimidazol-2-YL)-4-(2-aminopyrimidine)piperidine derivatives | IL2, IL4, IL4I1 | HRH1 37/4885KCNH2 609/4885CHRM1 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.